Article

CZM in India

Carl Zeiss Meditec has opened its Center for Application and Research (CARIn) near the company?s 14-year-old sales and service company in Bangalore, India, in an effort to strengthen its presence in high-growth markets and target its investments in research and development projects.

CZM in India

Jena, Germany-Carl Zeiss Meditec has opened its Center for Application and Research (CARIn) near the company’s 14-year-old sales and service company in Bangalore, India, in an effort to strengthen its presence in high-growth markets and target its investments in research and development projects.

“In India, we are investing not only in the expansion of our sales and service network but also in product and application development. In this process, we are working very closely with our customers and partners in science,” said Michael Kaschke, PhD, president and chief executive officer (CEO) of Carl Zeiss AG and responsible for the Asia region on the executive board since Jan. 1, 2011.

Ludwin Monz, MBA, PhD, president and CEO of Carl Zeiss Meditec AG, said, “Innovations form the foundation of our strategy that makes the latest medical technology available to high-growth markets like India. In the past, we already succeeded in developing products tailored specifically to the needs of doctors in these countries. With our own CARin and a team of highly motivated staff, we can work even more closely with customers on site and integrate their needs even more effectively into our product developments.”

Research and development (R&D) activities include:

•Define products for growth markets like India or China;

•Develop new software to enhance workflow efficiency in doctors’ offices and hospitals;

•Develop clinical applications and studies; and

•Collaborate closely with medical research institutes, hospitals, and universities in India to develop medical techniques jointly.

The R&D work initially will focus on systems for use in ophthalmology. Ultimately, however, the company expects to expand the center’s R&D activities to include the entire product spectrum of Carl Zeiss Meditec. The first employees for the new center have been recruited. The capacity will be expanded to up to 50 staff in the mid-term.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.